- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Cipla's Q1 FY26 revenue reached INR6,957 crores (+4% YoY), with a robust 25.6% EBITDA margin and PAT up 10.2% to INR1,298 crores. India business grew 6% to INR3,000+ crores, eyeing stronger recovery despite a softer respiratory quarter. U.S. revenue was $226 million, fueled by Albuterol's 19.5% market share. New U.S. launches (Nano Paclitaxel, Nilotinib) and first biosimilar (Q2 FY26) are key. Generic Advair (H2 FY26) and Symbicort expected, aiming for ~$1 billion U.S. sales by FY27. Management holds FY26 EBITDA margin guidance (23.5-24.5%), confident in pipeline and efficiency. #CiplaEarnings #Pharma